The Center for Biosimilars® recaps the top news for the week of November 12, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of November 12.
Number 5: The Canadian Agency for Drugs and Technologies in Health has released a new report that explores international pricing policies related to biosimilars and the factors that facilitate their use.
Number 4: During its investor call last week, Coherus Biosciences revealed that it will launch its biosimilar pegfilgrastim, Udenyca, at a 33% discount to the reference Neulasta.
Number 3: A newly published systematic review investigated the safety and efficacy of switching between reference and biosimilar infliximab in patients with inflammatory disorders.
Number 2: Given the high cost of biologics that treat pediatric inflammatory bowel disease, biosimilars are emerging as an important cost-saving option that can prevent the premature termination of biologic therapy for financial reasons.
Number 1: Genentech recently filed a motion in a US district court seeking an injunction to block JHL Biotech from making and selling potential biosimilars after former Genentech employees were charged with conspiring to steal trade secrets.
Finally, last week, our e-newsletter asked if requiring manufacturers to disclose their insulin’s list pricing process would help curb costs.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
HHS Praises Biosimilars Savings but Opportunities to Reduce Part B Spending Remain
November 28th 2023Although biosimilars have already generated savings for Medicare Part B programs and beneficiaries, opportunities for substantial reductions in spending remain, according to a report from the HHS.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
Part 3: Study Questions Usefulness of Clinical Efficacy Trials for Oncology Biosimilars in Europe
November 16th 2023In part 3 of a 3-part series for Global Biosimilars Week, The Center for Biosimilars® reviews an analysis investigating whether clinical efficacy studies have an impact on prescribing decisions for oncology biosimilars across Europe.